Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7777 in Relapsed/Refractory PTCL and CTCL
NCT02676778Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Apr 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denileukin diftitox in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Eisai Co., Ltd. Primary endpoint: Objective Response Rate. Started Mar 2016; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02676778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676778.